Validation of Diacyl Glycerolacyltransferase I as a Novel Target for the Treatment of Obesity and Dyslipidemia Using a Potent and Selective Small Molecule InhibitorGang Zhao, Philip R. Kym, Andrew J. Souers et al.|Journal of Medicinal Chemistry|2008Cited by 140
Nonclinical Efficacy and Safety of CX-2029, an Anti-CD71 Probody–Drug ConjugateShweta Singh, Jennifer Richardson, Andrew Jang et al.|Molecular Cancer Therapeutics|2022Cited by 35
Abstract B116: Optimizing a CD71-targeting Probody drug conjugate (PDC) for activity in multiple solid tumor and lymphoma models and for tolerability in nonhuman primatesShweta Singh, Michael Kavanaugh, Laura Serwer et al.|Molecular Cancer Therapeutics|2018Cited by 5
Data from Nonclinical Efficacy and Safety of CX-2029, an Anti-CD71 Probody–Drug ConjugateShweta Singh, Jennifer Richardson, Laura Serwer et al.|Unknown|2023Cited by 0
Supplementary Data from Nonclinical Efficacy and Safety of CX-2029, an Anti-CD71 Probody–Drug ConjugateShweta Singh, Jennifer Richardson, Laura Serwer et al.|Unknown|2023Cited by 0